Idera Pharmaceuticals Inc (IDRA)

[koman]

The emphasis on today's PR is that these patients who responded with 2 PR and one CR are PD1 refractory Melanoma patients. In other words, they FAILED to respond to PD1 antibody treatment UNTIL they received the TLR 9 agonist IMO 2125. I would say that this is a CLEAR signal of efficacy for using TLR 9 agonist in combo treatment with CIs.

UNfortunately, the company did use this preliminary good news to couch the bad news of discontinuing two IMO-8400 programs. But I'm glad that this company will drop unpromising programs instead of wasting more money.

GL and JMHO